{"nctId":"NCT00356408","briefTitle":"Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease","startDateStruct":{"date":"2007-01"},"conditions":["Crohn's Disease"],"count":106,"armGroups":[{"label":"CDP870 400 mg","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab pegol"]}],"interventions":[{"name":"Certolizumab pegol","otherNames":["CDP870","CZP","Cimzia"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients previously enrolled in C87059 (COSPAR I, NCT00349752)\n\nExclusion Criteria:\n\n* Subject withdrawn or discontinued from C87059 (COSPAR I, NCT00349752) study under specific conditions\n* Subject who received treatment other than study medication and other than medications permitted in C87059 (COSPAR I, NCT00349752)\n* Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks)","description":"Results are presented as the number of subjects with at least one treatment-emergent adverse event during this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Remission (Crohn's Disease Activity Index, CDAIâ‰¤150) at Week 34 in Patients Who Completed/Did Not Complete C87059 (COSPAR I, NCT00349752) and Remained Off Corticosteroids.","description":"Crohn's disease activity index (CDAI) is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. Results are presented as the percentage of subjects in disease remission at Week 34.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"37.5","spread":null},{"groupId":"OG002","value":"35.0","spread":null},{"groupId":"OG003","value":"3.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":14},"commonTop":["Crohn's Disease","Arthralgia","Upper Respiratory Tract Infection","Nasopharyngitis","Nausea"]}}}